Table 6 Salvage therapy for esophageal cancer recurrence after definitive concurrent chemoradiotherapy
Study | Type of recurrence | N | Salvage treatment | Short-term effect | Long-term effect | Note |
|---|---|---|---|---|---|---|
Makazu, 2014 [47] | local | 11 | sEMR | R0 rate:84.6% | 5year OS 41.6% | If the lesion does not exceed the mucosal layer and there are no lymph nodes or distant metastases. |
Yano, 2008 [50] | local | 21 | sEMR | R0 rate:84.6% | 5year OS49.1% | |
Takeuchi, 2013 [51] | local | 19 | sESD | CR rate:94.7% | 3year OS 74.0% | / |
Hatogai, 2016 [52] | local | 113 | sPDT | CR rate:58.4% | 5year OS 35.9% | If the tumor invades the submucosa and sEMR treatment is unsuccessful. |
Matsutani, 2017 [53] | local | 12 | sAPC | CR rate:58.3% | 5year OS 47.0% | / |
Yoo C, 2012 [54] | local | 12 | Salvage Esophagectomy | / | 3year OS 58.0% | / |
Chen Y, 2014 [55] | local | 36 | Salvage Chemoradiation | / | 3year OS 12.2% | / |
Zhou ZG, 2015 [56] | local | 55 | Salvage Radiotherapy | / | 3year OS21.8% | / |
Jie Li, 2020 [56] | distant | 82 | Salvage Radiotherapy | / | MST (months) RT:14 NRT:7 (P = 0.016). | Compared with BED10 < 60 Gy, BED10 ≥ 60 Gy could further prolong the median OS (16months vs. 10 months). |